Cargando…
MCL-1 is a clinically targetable vulnerability in breast cancer
Pro-survival members of the BCL-2 family, including MCL-1, are emerging as important proteins during the development and therapeutic response of solid tumors. Notably, high levels of MCL-1 occur in breast cancer, where functional dependency has been demonstrated using cell lines and mouse models. Th...
Autores principales: | Winder, Matthew L, Campbell, Kirsteen J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278428/ https://www.ncbi.nlm.nih.gov/pubmed/35349392 http://dx.doi.org/10.1080/15384101.2022.2054096 |
Ejemplares similares
-
Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function
por: Campbell, Kirsteen J., et al.
Publicado: (2021) -
MCL-1 is a prognostic indicator and drug target in breast cancer
por: Campbell, Kirsteen J., et al.
Publicado: (2018) -
BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer
por: Yan, Gonghong, et al.
Publicado: (2022) -
Overexpression of Mcl-1 exacerbates lymphocyte accumulation and autoimmune kidney disease in lpr mice
por: Anstee, Natasha S, et al.
Publicado: (2017) -
Targeting MCL-1 in cancer: current status and perspectives
por: Wang, Haolan, et al.
Publicado: (2021)